Genelux (GNLX) Long-Term Investments (2023 - 2024)

Genelux's (GNLX) quarterly Long-Term Investments came in at $1.0 million in Q3 2024, down 85.28% quarter-over-quarter from $6.8 million in Q2 2024.

Genelux (GNLX) Long-Term Investments (2023 - 2024) Analysis & Trends

Genelux's Long-Term Investments history runs 2 years deep, the most recent figure standing at $1.0 million for Q3 2024.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $1.0 million in Q3 2024; TTM through Sep 2024 was $1.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $24000.0, changed N/A from the prior year.
Long-Term Investments eased to $1.0 million in Q3 2024 per GNLX's latest filing, from $6.8 million in the prior quarter.
Across five years, Long-Term Investments topped out at $6.8 million in Q2 2024 and bottomed at $24000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	505,194.89
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Genelux	129.36 Mn	129.36 Mn	-	-

Download Data